Identification of the enzyme responsible for oxidative halothane metabolism: Implications for prevention of halothane hepatitis

Lancet

Volumn 347, Issue 9012, 1996, Pages 1367-1371

  Kharasch, Evan D ^a   Hankins, Douglas ^a   Mautz, Douglas ^a   Thummel, Kenneth E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMIDE; CYTOCHROME P450; DISULFIRAM; DRUG METABOLIZING ENZYME; FLUORIDE; HALOTHANE; TRIFLUOROACETIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; INHALATIONAL DRUG ADMINISTRATION; LIVER NECROSIS; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; URINE LEVEL;

EID: 0029984604     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)91011-9     Document Type: Article

References (30)

1. Ray DC, Drummond GB. Halothane hepatitis. Br J Anaesth 1991; 67: 84-99.
2. Cousins MJ, Plummer JL, Hall PM. Risk factors for halothane hepatitis. Aust NZ J Surg 1989; 59: 5-14.
3. Kenna JG, Martin JL, Satoh H, Pohl LR. Factors affecting the expression of trifluoroacetylated liver microsomal protein neoantigens in rats treated with halothane. Drug Metab Disp 1990; 18: 788-93.
4. Pohl LR, Kenna JG, Satoh H, Christ DD, Martin JL. Neoantigens associated with halothane-hepatitis. Drug Metab Rev 1989; 20: 203-17.
5. Loesch J, Siegers C-P, Younes M. Influence of cimetidine and diethyldithiocarbamate on the metabolism of halothane and methoxyflurane in vitro. Pharmacol Res Commun 1987; 19: 395-403.
6. Gruenke LD, Konopka K, Koop DR, Waskell LA. Characterization of halothane oxidation by hepatic microsomes and purified cytochromes P-450 using a gas chromatographic mass spectrometric assay. J Pharmacol Exp Ther 1988; 246: 454-59.
7. Eckes L, Buch HP. Influence of disulfiram, diethyldithiocarbamate and carbon disulfide on the metabolic formation of trifluoroacetic acid from halothane in the rat. Arzneim Forsch 1985; 35: 1447-51.
8. Rice SA, Maze MR, Smith CM, Kosek, JC, Mazze RI. Halothane hepatotoxicity in Fischer 344 rats pretreated with isoniazid. Toxicol Appl Pharmacol 1987; 87: 411-19.
9. Urban G, Speerschneider P, Dekant W. Metabolism of the chlorofluorocarbon substitute 1,1-dichloro-2,2,2-trifluoroethane by rat and human liver microsomes: the role of cytochrome P450 2E1. Chem Res Toxicol 1994; 7: 170-76.
10. Brown RM, Taleishi T, Guengerich FP, Wood M, Wood AJJ. Halothane microsomal oxidation is inhibited by diethyldithiocarbamate, an inhibitor of CYP2E1. Anesth Analg 1995; 80: S60.
11. Thummel KE, Kharasch ED, Podoll T, Kunze K. Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1. Drug Metab Dispos 1993; 21: 350-57.
12. Kharasch ED, Thummel KE. Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane and methoxyflurane. Anesthesiology 1993; 79: 795-807.
13. Kharasch ED, Thummel KE, Mautz D, Bosse S. Clinical enflurane metabolism by cytochrome P450 2E1. Clin Pharmacol Ther 1994; 55: 434-40.
14. Kharasch ED, Armstrong AS, Gunn K, Artru A, Cox K. Clinical sevoflurane metabolism and disposition: II, the role of cytochrome P450 2E1 in fluoride and hexafluoroisopropanol formation. Anesthesiology 1995; 82: 1379-88.
15. Kharasch ED, Thummel K, Mhyre J, Lillibridge J. Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1. Clin Pharmacol Ther 1993; 53: 643-50.
16. Baker MT, Chadam MV, Ronnenberg WC. Inhibitory effects of propofol on cytochrome P450 activities in rat hepatic microsomes. Anesth Analg 1993; 76: 817-21.
17. Kawaguchi R, Fujii K, Morio M, Yuge O, Hossain D. Determination by ion-exchange chromatography of trifluoroacetic acid as a biliary metabolite of isoflurane in the rabbit. Hiroshima J Med Sci 1989; 38: 27-34.
18. Guengerich FP, Kim D-H, Iwasaki M. Role of human P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991; 4: 168-79.
19. Newton DJ, Wang RW, Lu AYH. Cytochrome P450 inhibitors. Evaluations of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995; 23: 154-58.
20. Yamazaki H, Inui Y, Yun C-H, Guengerich FP, Shimada T. Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 1992; 13: 1789-94.
21. Young SR, Stoelting RK, Peterson C, Madura JA. Anesthetic biotransformation and renal function in obese patients during and after methoxyflurane or halothane anesthesia. Anesthesiology 1975; 42: 451-57.
22. O'Shea D, Davis SN, Kim RB, Wilkinson GR. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther 1994; 56: 359-67.
23. Emery MG, Fisher JM, Peter RMM, Dellinger EP, Kharasch ED, Thummel KE. Decreased CYP2E1 activity following surgical treatment for morbid obesity. Int Soc Study Xenobiotics Proc 1995; 8: 168.
24. Koop DR, Tierney DJ. Multiple mechanisms in the regulation of ethanol-inducible cytochrome P450IIE1. Bioessays 1990; 12: 429-35.
25. Cousins MJ, Sharp JH, Gourlay GK, Adams JF, Haynes WD, Whitehead R. Hepatotoxicity and halothane metabolism in an animal model with application for human toxicity. Anaesth Intens Care 1979; 7: 9-24.
26. Knights KM, Gourlay GK, Cousins MJ. Changes in rat hepatic microsomal mixed function oxidase activity following exposure to halothane under various oxygen concentrations. Biochem Pharmacol 1987; 36: 897-906.
27. Sakaguchi Y, Inaba S, Irita K, Sakai H, Nawata H, Takahashi S. Absence of anti-trifluoroacetate antibody after halothane anaesthesia in patients exhibiting no or mild liver damage. Can J Anaesth 1994; 41: 398-403.
28. Ilyin GP, Rissel M, Malledant Y, Tanguy M, Guillouzo A. Human hepatocytes express trifluoroacetylated neoantigens after in vitro exposure to halothane. Biochem Pharmacol 1994; 48: 561-67.
29. Wood M, Uetrecht J, Phythyon JM, et al. The effect of cimetidine on anesthetic metabolism and toxicity. Anesth Analg 1986; 65: 481-88.
30. Ray DC, Howie AF, Beckett GJ, Drummond GB. Preoperative cimetidine does not prevent subclinical halothane hepatotoxicity in man. Br J Anaesth 1989; 63: 531-35.